Corrigendum to “The use of cannabinoids as anticancer agents” [Prog. Neuro-Psychopharmacol. Biol. Psychiatry 64 (2016) 259–266](S0278584615001190)(10.1016/j.pnpbp.2015.05.010);The use of cannabinoids as anticancer agents

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 64, Issue , 2016, Pages 259-266

  Velasco, Guillermo ^a,b   Hernández Tiedra, Sonia ^a,b   Dávila, David ^a,b   Lorente, Mar ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Apoptosis; Autophagy; Cancer; Cannabinoid; Cell signaling; Combinational therapy

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; ALECTINIB; ANANDAMIDE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CRIZOTINIB; DEXANABINOL; GELATINASE A; INHIBITOR OF DIFFERENTIATION 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN KINASE B; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; WIN 55 2121 2; ANTINEOPLASTIC AGENT; CANNABINOID; ENDOCANNABINOID;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; BRAIN CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENESIS; CELL ADHESION; CELL DEATH; CELL MIGRATION; CELL VIABILITY; CONVULSION; COORDINATION DISORDER; DOWN REGULATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; ENDOPLASMIC RETICULUM STRESS; GLIOBLASTOMA; HUMAN; LYMPHOMA; METASTASIS POTENTIAL; NONHUMAN; PROTEIN EXPRESSION; PSYCHOSIS; REVIEW; SOLID TUMOR; TUMOR INVASION; UPREGULATION; ANIMAL; CLINICAL TRIAL (TOPIC); METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CANNABINOIDS; CLINICAL TRIALS AS TOPIC; ENDOCANNABINOIDS; HUMANS; NEOPLASMS;

EID: 84941189206     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2016.12.005     Document Type: Erratum

References (103)

1. Andradas C., Caffarel M.M., Perez-Gomez E., Salazar M., Lorente M., Velasco G., et al. The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 2011, 30(2):245-252.
2. Armstrong J.L., Hill D.S., McKee C.S., Hernandez-Tiedra S., Lorente M., Lopez-Valero I., et al. Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death. J Invest Dermatol 2015, 135(6):1629-1637.
3. Atwood B.K., Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 2010, 160(3):467-479.
4. Benz A.H., Renne C., Maronde E., Koch M., Grabiec U., Kallendrusch S., et al. Expression and functional relevance of cannabinoid receptor 1 in Hodgkin lymphoma. PLoS One 2013, 8(12):e81675.
5. Bifulco M., Laezza C., Portella G., Vitale M., Orlando P., De Petrocellis L., et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 2001, 15(14):2745-2747.
6. Blazquez C., Casanova M.L., Planas A., Gómez del Pulgar T., Villanueva C., Fernandez-Acenero M.J., et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 2003, 17(3):529-531.
7. Blazquez C., Gonzalez-Feria L., Alvarez L., Haro A., Casanova M.L., Guzman M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 2004, 64(16):5617-5623.
8. Blazquez C., Carracedo A., Barrado L., Real P.J., Fernandez-Luna J.L., Velasco G., et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J 2006, 20(14):2633-2635.
9. Blazquez C., Salazar M., Carracedo A., Lorente M., Egia A., Gonzalez-Feria L., et al. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res 2008, 68(6):1945-1952.
10. Caffarel M.M., Sarrio D., Palacios J., Guzman M., Sanchez C. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 2006, 66(13):6615-6621.
11. Caffarel M.M., Andradas C., Mira E., Perez-Gomez E., Cerutti C., Moreno-Bueno G., Flores J.M., Garcia-Real I., Palacios J., Manes S., Guzman M., Sanchez C. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer. 2010, 9:196.
12. Caffarel M.M., Sarrio D., Palacios J., Guzman M., Sanchez C. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer research. 2006, 66:6615-6621.
13. Caffarel M.M., Andradas C., Perez-Gomez E., Guzman M., Sanchez C. Cannabinoids: a new hope for breast cancer therapy?. Cancer Treat Rev 2012, 38(7):911-918.
14. Carracedo A., Gironella M., Lorente M., Garcia S., Guzman M., Velasco G., et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 2006, 66(13):6748-6755.
15. Carracedo A., Lorente M., Egia A., Blazquez C., Garcia S., Giroux V., et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 2006, 9(4):301-312.
16. Casanova M.L., Blazquez C., Martinez-Palacio J., Villanueva C., Fernandez-Acenero M.J., Huffman J.W., et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003, 111(1):43-50.
17. Chan P.C., Sills R.C., Braun A.G., Haseman J.K., Bucher J.R. Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam Appl Toxicol 1996, 30(1):109-117.
18. Chung S.C., Hammarsten P., Josefsson A., Stattin P., Granfors T., Egevad L., et al. A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer 2009, 45(1):174-182.
19. Cudaback E., Marrs W., Moeller T., Stella N. The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas. PLoS One 2010, 5(1):e8702.
20. de Bono J.S., Ashworth A. Translating cancer research into targeted therapeutics. Nature 2010, 467(7315):543-549.
21. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258(5090):1946-1949.
22. Donadelli M., Dando I., Zaniboni T., Costanzo C., Dalla Pozza E., Scupoli M.T., et al. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis 2011, 2:e152.
23. Eisenberg-Lerner A., Bialik S., Simon H.U., Kimchi A. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 2009, 16(7):966-975.
24. Ek S., Hogerkorp C.M., Dictor M., Ehinger M., Borrebaeck C.A. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res 2002, 62(15):4398-4405.
25. Feigenbaum J.J., Bergmann F., Richmond S.A., Mechoulam R., Nadler V., Kloog Y., et al. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc Natl Acad Sci U S A 1989, 86(23):9584-9587.
26. Fernandez-Ruiz J., Romero J., Velasco G., Tolon R., Ramos J., Guzman M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival?. Trends Pharmacol Sci 2007, 28(1):39-45.
27. Galluzzi L., Pietrocola F., Bravo-San Pedro J.M., Amaravadi R.K., Baehrecke E.H., Cecconi F., et al. Autophagy in malignant transformation and cancer progression. EMBO J 2015, 34(7):856-880.
28. Galve-Roperh I., Sanchez C., Cortes M.L., Gómez del Pulgar T., Izquierdo M., Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000, 6(3):313-319.
29. Galve-Roperh I., Aguado T., Palazuelos J., Guzman M. Mechanisms of control of neuron survival by the endocannabinoid system. Curr Pharm Des 2008, 14(23):2279-2288.
30. Gomez del Pulgar T., Velasco G., Sanchez C., Haro A., Guzman M. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J 2002, 363(Pt 1):183-188.
31. Grande E., Bolos M.V., Arriola E. Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol Cancer Ther 2011, 10(4):569-579.
32. Grimaldi C., Pisanti S., Laezza C., Malfitano A.M., Santoro A., Vitale M., et al. Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 2006, 312(4):363-373.
33. Gustafsson K., Wang X., Severa D., Eriksson M., Kimby E., Merup M., et al. Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation. Int J Cancer 2008, 123(5):1025-1033.
34. Gustafsson S.B., Lindgren T., Jonsson M., Jacobsson S.O. Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. Cancer Chemother Pharmacol 2009, 63(4):691-701.
35. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003, 3(10):745-755.
36. Guzman M., Duarte M.J., Blazquez C., Ravina J., Rosa M.C., Galve-Roperh I., et al. A pilot clinical study of delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 2006, 95(2):197-203.
37. Hart S., Fischer O.M., Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 2004, 64(6):1943-1950.
38. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10):997-1003.
39. Islam T.C., Asplund A.C., Lindvall J.M., Nygren L., Liden J., Kimby E., et al. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of cyclin D1 in mantle cell lymphoma. Leukemia 2003, 17(9):1880-1890.
40. Joosten M., Valk P.J., Jorda M.A., Vankan-Berkhoudt Y., Verbakel S., van den Broek M., et al. Leukemic predisposition of pSca-1/Cb2 transgenic mice. Exp Hematol 2002, 30(2):142-149.
41. Jung C.K., Kang W.K., Park J.M., Ahn H.J., Kim S.W., Taek Oh S., et al. Expression of the cannabinoid type I receptor and prognosis following surgery in colorectal cancer. Oncol Lett 2013, 5(3):870-876.
42. Kadomatsu K. The midkine family in cancer, inflammation and neural development. Nagoya J Med Sci 2005, 67(3-4):71-82.
43. Katona I., Freund T.F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 2008, 14(9):923-930.
44. Ligresti A., Bisogno T., Matias I., De Petrocellis L., Cascio M.G., Cosenza V., et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003, 125(3):677-687.
45. Ligresti A., Moriello A.S., Starowicz K., Matias I., Pisanti S., De Petrocellis L., et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 2006, 318(3):1375-1387.
46. Lonardi S., Tosoni A., Brandes A.A. Adjuvant chemotherapy in the treatment of high grade gliomas. Cancer Treat Rev 2005, 31(2):79-89.
47. Lorente M., Carracedo A., Torres S., Natali F., Egia A., Hernandez-Tiedra S., et al. Amphiregulin is a factor for resistance of glioma cells to cannabinoid-induced apoptosis. Glia 2009, 57(13):1374-1385.
48. Lorente M., Torres S., Salazar M., Carracedo A., Hernandez-Tiedra S., Rodriguez-Fornes F., et al. Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action. Cell Death Differ 2011, 18(6):959-973.
49. Malfitano A.M., Ciaglia E., Gangemi G., Gazzerro P., Laezza C., Bifulco M. Update on the endocannabinoid system as an anticancer target. Expert Opin Ther Targets 2011, 15(3):297-308.
50. Marcu J.P., Christian R.T., Lau D., Zielinski A.J., Horowitz M.P., Lee J., et al. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther 2010, 9(1):180-189.
51. Massi P., Valenti M., Vaccani A., Gasperi V., Perletti G., Marras E., et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 2008, 104(4):1091-1100.
52. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346(6284):561-564.
53. McAllister S.D., Murase R., Christian R.T., Lau D., Zielinski A.J., Allison J., et al. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat 2011, 129(1):37-47.
54. McKallip R.J., Nagarkatti M., Nagarkatti P.S. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol 2005, 174(6):3281-3289.
55. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995, 50(1):83-90.
56. Messalli E.M., Grauso F., Luise R., Angelini A., Rossiello R. Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors. Am J Obstet Gynecol 2014, 211(3):234.e231-234.e236.
57. Michalski C.W., Oti F.E., Erkan M., Sauliunaite D., Bergmann F., Pacher P., et al. Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer 2008, 122(4):742-750.
58. Mirkin B.L., Clark S., Zheng X., Chu F., White B.D., Greene M., et al. Identification of midkine as a mediator for intercellular transfer of drug resistance. Oncogene 2005, 24(31):4965-4974.
59. Miyato H., Kitayama J., Yamashita H., Souma D., Asakage M., Yamada J., et al. Pharmacological synergism between cannabinoids and paclitaxel in gastric cancer cell lines. J Surg Res 2009, 155(1):40-47.
60. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451(7182):1069-1075.
61. Moreno E., Andradas C., Medrano M., Caffarel M.M., Perez-Gomez E., Blasco-Benito S., et al. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. J Biol Chem 2014, 289(32):21960-21972.
62. Mrugala M.M. Advances and challenges in the treatment of glioblastoma: a clinician's perspective. Discov Med 2013, 15(83):221-230.
63. Mukhopadhyay B., Schuebel K., Mukhopadhyay P., Cinar R., Godlewski G., Xiong K., et al. Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Hepatology 2015, 61(5):1615-1626.
64. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365(6441):61-65.
65. Murase R., Kawamura R., Singer E., Pakdel A., Sarma P., Judkins J., et al. Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. Br J Pharmacol 2014, 171(19):4464-4477.
66. Nabissi M., Morelli M.B., Santoni M., Santoni G. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis 2012, 34(1):48-57.
67. Nomura D.K., Long J.Z., Niessen S., Hoover H.S., Ng S.W., Cravatt B.F. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010, 140(1):49-61.
68. Pacher P., Batkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006, 58(3):389-462.
69. Pall G. The next-generation ALK inhibitors. Curr Opin Oncol 2015, 27(2):118-124.
70. Palmer R.H., Vernersson E., Grabbe C., Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009, 420(3):345-361.
71. Perez-Gomez E., Andradas C., Flores J.M., Quintanilla M., Paramio J.M., Guzman M., et al. The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene 2013, 32(20):2534-2542.
72. Perez-Gomez E., Andradas C., Blasco-Benito S., Caffarel M.M., Garcia-Taboada E., Villa-Morales M., et al. Role of cannabinoid receptor CB2 in HER2 Pro-oncogenic signaling in breast cancer. J Natl Cancer Inst 2015, 107(6).
73. Pertwee R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009, 156(3):397-411.
74. Pertwee R.G., Howlett A.C., Abood M.E., Alexander S.P., Di Marzo V., Elphick M.R., et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010, 62(4):588-631.
75. Pisanti S., Borselli C., Oliviero O., Laezza C., Gazzerro P., Bifulco M. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. J Cell Physiol 2007, 211(2):495-503.
76. Pisanti S., Picardi P., D'Alessandro A., Laezza C., Bifulco M. The endocannabinoid signaling system in cancer. Trends Pharmacol Sci 2013, 34(5):273-282.
77. Portella G., Laezza C., Laccetti P., De Petrocellis L., Di Marzo V., Bifulco M. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 2003, 17(12):1771-1773.
78. Preet A., Ganju R.K., Groopman J.E. Delta9-tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 2008, 27(3):339-346.
79. Qamri Z., Preet A., Nasser M.W., Bass C.E., Leone G., Barsky S.H., et al. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther 2009, 8(11):3117-3129.
80. Ramer R., Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst 2008, 100(1):59-69.
81. Sailler S., Schmitz K., Jager E., Ferreiros N., Wicker S., Zschiebsch K., et al. Regulation of circulating endocannabinoids associated with cancer and metastases in mice and humans. Oncoscience 2014, 1(4):272-282.
82. Salazar M., Carracedo A., Salanueva I.J., Hernandez-Tiedra S., Lorente M., Egia A., et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest 2009, 119(5):1359-1372.
83. Salazar M., Lorente M., Garcia-Taboada E., Hernandez-Tiedra S., Davila D., Francis S.E., et al. The pseudokinase tribbles homologue-3 plays a crucial role in cannabinoid anticancer action. Biochim Biophys Acta 2013, 1831(10):1573-1578.
84. Sanchez C., de Ceballos M.L., del Pulgar T.G., Rueda D., Corbacho C., Velasco G., et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 2001, 61(15):5784-5789.
85. Sarfaraz S., Adhami V.M., Syed D.N., Afaq F., Mukhtar H. Cannabinoids for cancer treatment: progress and promise. Cancer Res 2008, 68(2):339-342.
86. Scott K.A., Dalgleish A.G., Liu W.M. The combination of cannabidiol and Delta9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Mol Cancer Ther 2014, 13(12):2955-2967.
87. Shrivastava A., Kuzontkoski P.M., Groopman J.E., Prasad A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther 2011, 10(7):1161-1172.
88. Soroceanu L., Murase R., Limbad C., Singer E.L., Allison J., Adrados I., et al. Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res 2012, 73(5):1559-1569.
89. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996.
90. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995, 215(1):89-97.
91. Thors L., Bergh A., Persson E., Hammarsten P., Stattin P., Egevad L., et al. Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. PLoS One 2010, 5(8):e12275.
92. Torres S., Lorente M., Rodriguez-Fornes F., Hernandez-Tiedra S., Salazar M., Garcia-Taboada E., et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 2011, 10(1):90-103.
93. Vara D., Salazar M., Olea-Herrero N., Guzman M., Velasco G., Diaz-Laviada I. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ 2011, 18(7):1099-1111.
94. Vara D., Morell C., Rodriguez-Henche N., Diaz-Laviada I. Involvement of PPARgamma in the antitumoral action of cannabinoids on hepatocellular carcinoma. Cell Death Dis 2013, 4:e618.
95. Velasco G., Sanchez C., Guzman M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 2012, 12(6):436-444.
96. Wallace GCt, Dixon-Mah Y.N., Vandergrift W.A., Ray S.K., Haar C.P., Mittendorf A.M., et al. Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma. Metab Brain Dis 2013, 28(3):355-366.
97. Wang D., Wang H., Ning W., Backlund M.G., Dey S.K., DuBois R.N. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res 2008, 68(15):6468-6476.
98. Wasik A.M., Almestrand S., Wang X., Hultenby K., Dackland A.L., Andersson P., et al. WIN55,212-2 induces cytoplasmic vacuolation in apoptosis-resistant MCL cells. Cell Death Dis 2011, 2:e225.
99. Wasik A.M., Nygren L., Almestrand S., Zong F., Flygare J., Wennerholm S.B., et al. Perturbations of the endocannabinoid system in mantle cell lymphoma: correlations to clinical and pathological features. Oncoscience 2014, 1(8):550-557.
100. Wu X., Han L., Zhang X., Li L., Jiang C., Qiu Y., et al. Alteration of endocannabinoid system in human gliomas. J Neurochem 2012, 120(5):842-849.
101. Xu X., Liu Y., Huang S., Liu G., Xie C., Zhou J., Fan W., Li Q., Wang Q., Zhong D., Miao X. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet. 2006, 171:31-38.
102. Zheng D., Bode A.M., Zhao Q., Cho Y.Y., Zhu F., Ma W.Y., et al. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res 2008, 68(10):3992-3998.
103. Zhu L.X., Sharma S., Stolina M., Gardner B., Roth M.D., Tashkin D.P., et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 2000, 165(1):373-380.